155 related articles for article (PubMed ID: 16882055)
1. Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer.
Kato T; Suzuki H; Komiya A; Imamoto T; Naya Y; Tobe T; Ichikawa T
Int J Urol; 2006 Jul; 13(7):915-9. PubMed ID: 16882055
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
[TBL] [Abstract][Full Text] [Related]
3. Role of sterile pyuria in association to elevated PSA values in the diagnosis of non-palpable prostate cancer?
Demir S
Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577101
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
5. Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study.
Seo HK; Chung MK; Ryu SB; Lee KH;
Urology; 2007 Dec; 70(6):1109-12. PubMed ID: 18158028
[TBL] [Abstract][Full Text] [Related]
6. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
7. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
9. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
Inahara M; Suzuki H; Kojima S; Komiya A; Fukasawa S; Imamoto T; Naya Y; Ichikawa T
Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
11. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
12. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients.
Guichard G; Larré S; Gallina A; Lazar A; Faucon H; Chemama S; Allory Y; Patard JJ; Vordos D; Hoznek A; Yiou R; Salomon L; Abbou CC; de la Taille A
Eur Urol; 2007 Aug; 52(2):430-5. PubMed ID: 17412489
[TBL] [Abstract][Full Text] [Related]
13. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
[TBL] [Abstract][Full Text] [Related]
14. Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
Tekin A; Yuksel A; Tekin S; Gumrukcu G; Aslan AR; Sengor F
J Urol; 2009 Aug; 182(2):564-8; discussion 568-9. PubMed ID: 19524953
[TBL] [Abstract][Full Text] [Related]
15. [The assessment of pathological PSA values by the general practitioner--observation or intervention?].
Braun KP; Brookman-Amissah S; May M; Grassmel Y; Hoschke B; Braun V
Aktuelle Urol; 2009 May; 40(3):171-4. PubMed ID: 19479670
[TBL] [Abstract][Full Text] [Related]
16. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
17. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
19. Do changes in a high serum prostate-specific antigen level and the free/total prostate-specific antigen ratio after antibiotic treatment rule out biopsy and the suspicion of cancer?
Dirim A; Tekin MI; Koyluoglu E; Oguzulgen AI; Peskircioglu L; Ozkardes H
Urol Int; 2009; 82(3):266-9. PubMed ID: 19440011
[TBL] [Abstract][Full Text] [Related]
20. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
